Glax­o­SmithK­line punts a key Ze­ju­la com­bo study in ovar­i­an can­cer with added set­backs on ICOS and RSV

A chink has ap­peared in the ar­mor of da­ta that Glax­o­SmithK­line R&D chief Hal Bar­ron has been build­ing for the PARP in­hibitor Ze­ju­la.

The phar­ma gi­ant’s Q2 up­date on Wednes­day in­cludes the note that re­searchers have end­ed their Phase II MOON­STONE study, one of a slate of tri­als that Bar­ron has cit­ed to “help es­tab­lish Ze­ju­la as the most com­pelling PARP in­hibitor for women with ovar­i­an can­cer.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER